March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

By Tom Wilemon

April 18, 2019

Medical Societies honor multiple Vanderbilt faculty

Several Vanderbilt faculty members were recently honored during the joint annual meeting of the Association of American Physicians (AAP) and American Society for Clinical Investigation (ASCI).

By Bill Snyder

March 3, 2016

Melanoma response to immune therapy

Melanoma-specific expression of a certain protein identifies tumors that are more responsive to an immune therapy.

By Leigh MacMillan

October 29, 2015

Investigators find clues to melanoma treatment resistance

Nearly half of all patients with malignant melanoma, the most deadly form of skin cancer, have a mutation in the BRAF gene found in their tumors. Mutations in the BRAF gene turn on a cancer growth switch known as the MAP kinase pathway.

By Vanderbilt Health News

March 12, 2015

Gene mutations may predict melanoma response to immunotherapies

Melanoma patients whose tumors test positive for mutations in the NRAS gene were more likely to benefit from new immunotherapy drugs, according to a new study led by Vanderbilt-Ingram Cancer Center (VICC) investigators.

By Vanderbilt Health News